Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07474649 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

StatusNot Yet Recruiting
PhasePhase 3
Started2026-09-30
View on ClinicalTrials.gov ↗

Amendment history

2026-08-04
Study Status, Contacts/Locations v3
Trial sites expanded: 0 → 12 locations
Start date2026-07-31→2026-08-15
2026-07-21
Study Status v2
Start date2026-06-01→2026-07-31
2026-03-16
Study Status, Sponsor/Collaborators, Conditions, Outcome Measures v1
Lead sponsorDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company→Daiichi Sankyo
Secondary endpointsdetails revised at 1 of 16 entries
2026-03-11
Original filing
The overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin on changes in coronary plaque burden and plaque morphology in patients with coronary atherosclerosis without significant obstructive coronary artery disease and without prior history of an ischemic vascular event.
Trial Details
NCT Number NCT07474649
Lead Sponsor Daiichi Sankyo
Conditions Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia
Enrollment 103 participants
Start Date 2026-09-30
Primary Completion 2028-06-01 (estimated)
Study Completion 2028-10-02 (estimated)
Updated on ClinicalTrials.gov 2026-09-29